Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Vera Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BRISBANE, CALIF., SEPT. 04, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT, ON SEPTEMBER 1, 2026, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS (COMPENSATION COMMITTEE) OF VERA THERAPEUTICS GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 61,500 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) UNDERLYING 30,750 SHARES OF CLASS A COMMON STOCK TO SIX (6) NEW EMPLOYEES UNDER THE VERA THERAPEUTICS, INC. 2024 INDUCEMENT PLAN (INDUCEMENT PLAN).

VERA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BRISBANE, CALIF., SEPT. 01, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A COMMERCIAL-STAGE BIOTECHNOLOGY COMPANY, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT TEAM WILL PRESENT AND PARTICIPATE IN ONE-ON-ONE MEETINGS AT UPCOMING INVESTOR CONFERENCES.

VERA THERAPEUTICS TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

BRISBANE, CALIF., AUG. 07, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT, ON AUGUST 3, 2026, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS (COMPENSATION COMMITTEE) OF VERA THERAPEUTICS GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 63,011 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) UNDERLYING 44,987 SHARES OF CLASS A COMMON STOCK TO NANCY BOWMAN, M.D.

BRISBANE, CALIF., JULY 10, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT, ON JULY 6, 2026, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS (COMPENSATION COMMITTEE) OF VERA THERAPEUTICS GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 32,100 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) UNDERLYING 16,050 SHARES OF CLASS A COMMON STOCK TO EIGHT (8) NEW EMPLOYEES UNDER THE VERA THERAPEUTICS, INC. 2024 INDUCEMENT PLAN (INDUCEMENT PLAN).

BRISBANE, CALIF., JULY 09, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A COMMERCIAL-STAGE BIOTECHNOLOGY COMPANY, TODAY ANNOUNCED A PLANNED TRANSITION OF THE CHIEF REGULATORY OFFICER POSITION.

VERA THERAPEUTICS ANNOUNCES APPOINTMENT OF NANCY BOMAN AS CHIEF REGULATORY OFFICER AND PLANNED RETIREMENT OF WILLIAM TURNER

TRUTAKNA IS THE FIRST AND ONLY AVAILABLE THERAPY THAT BINDS BOTH B-CELL ACTIVATING FACTOR (BAFF) AND A PROLIFERATION-INDUCING LIGAND (APRIL), ADDRESSING THE IMMUNOLOGICAL DRIVERS AT THE SOURCE OF IGA NEPHROPATHY (IGAN).1,2 THE TRUTAKNA DOSE IS 150 MG INJECTED SUBCUTANEOUSLY ONCE WEEKLY, SELF-ADMINISTERED VIA AN AUTOINJECTOR BY PATIENTS AT HOME.1 INVESTOR WEBCAST IS SCHEDULED FOR JULY 7 AT 4:30 PM EDT. A MEDIA SNIPPET ACCOMPANYING THIS ANNOUNCEMENT IS AVAILABLE BY CLICKING ON THIS LINK.

VERA THERAPEUTICS RECEIVES FDA ACCELERATED APPROVAL FOR TRUTAKNA FOR ADULT PATIENTS WITH PRIMARY IGA NEPHROPATHY

BRISBANE, CALIF., JUNE 05, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT, ON JUNE 2, 2026, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS (COMPENSATION COMMITTEE) OF VERA THERAPEUTICS GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 28,800 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) UNDERLYING 14,150 SHARES OF CLASS A COMMON STOCK TO TEN (10) NEW EMPLOYEES UNDER THE VERA THERAPEUTICS, INC. 2024 INDUCEMENT PLAN (INDUCEMENT PLAN).

VERA THERAPEUTICS ANNOUNCES ALIGNMENT WITH U.S. FDA ON EARLIER ORIGIN PHASE 3 ANALYSIS TO SUPPORT POTENTIAL FULL APPROVAL FOR ATACICEPT IN ADULTS WITH IGAN

VERA THERAPEUTICS ANNOUNCES ALIGNMENT WITH U.S. FDA ON EARLIER ORIGIN PHASE 3 ANALYSIS TO SUPPORT POTENTIAL FULL APPROVAL FOR ATACICEPT IN ADULTS WITH IGA NEPHROPATHY

BRISBANE, CALIF., MAY 08, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA) TODAY ANNOUNCED THAT, ON MAY 4, 2026, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS (COMPENSATION COMMITTEE) OF VERA THERAPEUTICS GRANTED INDUCEMENT AWARDS CONSISTING OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 40,250 SHARES OF CLASS A COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) UNDERLYING 20,125 SHARES OF CLASS A COMMON STOCK TO TEN (10) NEW EMPLOYEES UNDER THE VERA THERAPEUTICS, INC. 2024 INDUCEMENT PLAN (INDUCEMENT PLAN).

U.S. FOOD AND DRUG ADMINISTRATION (FDA) GRANTED PRIORITY REVIEW TO BIOLOGICS LICENSE APPLICATION (BLA) FOR THE ACCELERATED APPROVAL OF ATACICEPT IN ADULT PATIENTS WITH IGA NEPHROPATHY (IGAN) WITH A PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE OF JULY 7, 2026 ON TRACK FOR U.S. COMMERCIAL LAUNCH OF ATACICEPT IN MID-2026, PENDING REGULATORY APPROVAL STRONG BALANCE SHEET EXPECTED TO BE SUFFICIENT TO FUND OPERATIONS BEYOND POTENTIAL ATACICEPT APPROVAL AND U.S. COMMERCIAL LAUNCH BRISBANE, CALIF., MAY 07, 2026 (GLOBE NEWSWIRE) -- VERA THERAPEUTICS, INC. (NASDAQ: VERA), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING TRANSFORMATIVE TREATMENTS FOR PATIENTS WITH SERIOUS IMMUNOLOGICAL DISEASES, TODAY REPORTED ITS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026.

Vera Therapeutics, Inc.

VERA

Price

Financial Reports

No items found.

Press Releases

Vera Therapeutics, Inc.

VERA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

VERA